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ABSTRACT 
 
 
Mrp2 is an organic anion and bile salt export pump that must be translocated from 
the cytoplasm to the hepatocyte tubule canalicular membrane to transport its substrate.  
Although cAMP has been shown to induce both Mrp2 translocation and PKCδ activation, 
the interdependency of those two events has not been established.  Hepatocytes were 
treated with a cAMP analogue and/or bistratene A (a known activator of PKCδ) at 
varying concentrations, followed by biotinylation of cell surface protein, preparation of 
cell lysates, immunoprecipitation by streptavidin, and western analysis of Mrp2 levels.  
Like cAMP, bistratene A also induced Mrp2 translocation, and the combined effects were 
not additive, indicating that cAMP translocates Mrp2 by activating PKCδ. 
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BACKGROUND INFORMATION 
 
Bile Salts 
Bile Salt Physiology 
 The liver has many important functions, one of which is to form bile and recycle 
bile acids (Ganong, 1977).  Bile plays an important physiological role in the digestion of 
fats.  Stored in the gallbladder between meals, bile is released into the small intestine 
when CCK, an enzyme activated by the presence of food in the duodenum, stimulates the 
gallbladder to contract (Cunningham, 1992).  Bile acids are a major constituent of bile, 
and in conjunction with pancreatic lipase and other solutes in the bile, they help to 
emulsify fat by forming micelles, thereby helping lipid digestion and absorption 
(Cunningham, 1992).  Bile is also a major route by which cholesterol, bilirubin, 
hormones, some drugs, and some toxins are eliminated from the body (Nathanson and 
Boyer, 1991; Boyer and Nathanson, 1999). 
 These bile salts are recycled through the intestine, liver, and gallbladder, and this 
is referred to as enterohepatic circulation; as much as 95% of bile salts in the intestine are 
reabsorbed by the liver (Ettinger, 1983).  Bile salts are absorbed back into the hepatocytes 
from portal blood via transport proteins in the basolateral membrane of hepatocytes 
(Anwer, 1993). The absorbed bile salts are then secreted into the canaliculi by another 
transporter.  
Hepatocytes secrete early bile into a network of tubules between hepatocytes 
called canaliculi, and this early bile is modified as it makes its way into the bile ducts and 
the gallbladder (Trauner and Boyer, 2003).  This secretion is driven by the active 
 6
transport of organic solutes (bile salts, phospholipids, cholesterol) into the canaliculi, and 
the other components of bile (water, electrolytes, non-electrolytes) soon follow (Sperber, 
1959).  The secretion of bile salts into the canaliculi is one of the strongest choleretic 
agents, providing an osmotic driving force to produce more bile (Swenson, 1977; Trauner 
et al, 1999). 
 
Bile Salt Uptake into Hepatocytes 
 In order to maintain the flow of enterohepatic circulation, bile salts must be taken 
up into the hepatocytes, lowering their concentration in enterohepatic blood.  This 
movement occurs across the basolateral (or sinusoidal) membrane of the hepatocytes.  
Because these bile salts are moving against a concentration gradient, this transport must 
be coupled with energetically favorable transport in order to provide the energy necessary 
to achieve the transport of the bile salts; this energy can be provided by coupling the 
transport to the sodium gradient achieved by the sodium-potassium ATPase pump, or by 
coupling the transport to anion exchange (Kullak-Ublick et al, 2000A). 
 Table 1 below shows a list of the main transporter proteins involved in the 
enterohepatic circulation of bile. 
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TABLE 1:  SUMMARY OF BILE SALT TRANSPORTERS.  A 
summary of all of the basolateral and canalicular protein transporters 
involved in enterohepatic circulation of bile (Trauner and Boyer, 2003). 
 
   
 
 Sodium taurocholate cotransport peptide (Ntcp) is the main protein responsible 
for uptake of conjugated bile salts (Hagenbuch and Meier, 1944).  The transporter brings 
in two sodium ions for every molecule of bile acid, using the sodium gradient established 
by the sodium/potassium ATP pump (Takikawa, 2002).   
 A family of polypeptide transporters, named the Organic Anion Transporting 
Polypeptides (OATP), is responsible for the rest of basolateral uptake of bile salts and 
organic solutes involved in the production of bile (Jacquemin et al, 1994).  In the rat 
liver, the OATP family is made up of Oatp1 and Oatp2 (Kayko et al, 1999A), of which 
the human orthologs are OATP2 (Konig et al, 2000) and LST-1 (Abe et al, 1999). Oatp1 
helps to transport bile salts, conjugated steroids, and some types of drugs (Kullak-Ublick 
et al, 1994; Eckhardt et al, 1999).  The driving force for this transport is utilizing the 
energy of transporting glutathione in the opposite direction (Li et al, 1998).  Oatp2, in the 
same family as Oatp1, helps to transport bile salts, cardiac sugars, and cyclic peptides, 
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(Noe et al, 1997; Reichel et al, 1999) whereas LST-1 helps in the uptake of taurocholate 
(Kayko et al, 1999B).  Oatp4, another member of the family, is a full length version of 
LST-1, and it is involved in transport of other organic solutes in addition to taurocholate 
(Cattori et al, 2000).  Figure 1 shows a diagram of the function of proteins Ntcp, Oatp-1, 
and Oatp-2.  Human correspondents exist to all of the rat transporters, but since this 
project focuses on Mrp2, the human correspondents of the other proteins are not 
discussed in this paper. 
 
 
FIGURE 1.  RAT BILE SALT TRANSPORTERS.  Illustrates the 
role of each transporter in the enterohepatic circulation of bile, as well 
as demonstrating the interactions between the transporters.  OA = 
organic anion, BA = bile acid, BA-glcA2 = bile acid glucuronide, GSH 
= reduced glutathione, BA-sul2 = bile acid sulfate (Takikawa, 2002). 
 
 
Bile Salt Secretion from Hepatocytes via the Canalicular Membrane 
 As stated earlier, the hepatocyte secretes bile salts and organic solutes into the 
canaliculus, a tubular network that drains into the bile duct.  This transport occurs at the 
canalicular membrane.  Because the concentration of bile salts in the bile itself is very 
high, these bile salts are being actively transported against a steep concentration gradient, 
and this transport is the rate limiting step in the transhepatic transport of bile salts 
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(Trauner and Boyer, 2003).  The murine transporters that accomplish this are the bile salt 
export pump (Bsep), as well as Mdr1, Mdr2, and Mrp2 (Trauner and Boyer, 2003). 
 The transporters on the canalicular membrane are members of the ATP binding 
cassette family (ABC transporters), which hydrolyze ATP to ADP and Pi to provide 
energy to transport solutes against a concentration gradient (Takikawa, 2002).  Bile salt 
export pump (Bsep) is the primary transporter of amidated bile acids (Gerloff et al, 1998), 
and in line with the protein being an ABC, the energy provided for this transport comes 
from the hydrolysis of ATP (Suchy et al, 1997; Stieger and Meier, 1998).  Bile acids 
transported by this protein include taurocholate, glycocholate, taurochenodeoxycholate, 
and tauroursodeoxycholate (Kullak-Ublik et al, 2000B; Meier and Stieger, 2002). 
Mutations that prevent this protein from functioning normally result in progressive 
familial intrahepatic cholestasis type 2 (PFIC2) (Jansen et al, 1999).   
 As mentioned earlier, the bile in the canaliculus is an early form of bile that is 
modified in order to become the bile that is used in the intestines.  Other solutes are 
added to this initial bile, one of which is the lipid phosphatidylcholine, and this lipid is 
excreted from the rodent canalicular membrane via Mdr2 (Oude Elferink et al, 1997), an 
ATP dependent flippase (Smit et al, 1993; Smith et al, 1994).  Another solute hepatocytes 
secrete via the canalicular membrane is bicarbonate, and bicarbonate is secreted via the 
Cl-/HCO3- anion exchanger two (AE2) (Medina, 1997).   
 The final canalicular transporter is multidrug resistance protein 2 (Mrp2), the 
protein of interest to this MQP report.  Thus, specifics of this protein will be discussed 
later in the background of the paper.  In short, Mrp2, an ABC transporter (Keppler and 
Konig, 1997; Stieger and Meier, 1998), is expressed in the liver and localized to the 
 10
canalicular membrane.  It is responsible for the secretion of non-bile salt organic anions 
(Paulusma and Oude Elferink, 1997), as well as glutathione conjugates, glucuronides, 
leukotriene C4 and divalent (but not monovalent) bile salts (Madon et al, 1997; Ito et al, 
1998).  Further details of Mrp2, including its sequence, structure, physiological role, 
changes under cholestatic conditions, and activation will be discussed later in the paper.   
The human proteins involved in bile acid transport are shown below in figure 2. 
 
 
FIGURE 2:  HUMAN BILE ACID TRANSPORTERS.  Illustrates 
the human orthologs of the murine bile acid transporters illustrated in 
figure 1 (Takikawa, 2002). 
 
 
Cholestasis 
 
 Cholestasis, in its most general terms, is a disease state characterized by decreased 
bile formation.  It can have many physiological effects, such as the accumulation of 
hepatocellular bile acids and cholesterol, which can have toxic effects (Jansen, 2000).  At 
high concentrations, bile acids can be cytotoxic, damage mitochondria, stimulate the 
formation of hepatic stellate cells, which produce collagen, induce apoptosis 
(programmed cell death), and have a direct effect on transcriptional regulation of 
enzymes and transporters (Jansen, 2000). 
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Cholestasis is usually associated with decreased transhepatic transport of bile 
acids at the basolateral or canalicular membrane by specific transporters present there 
(Meier and Steiger, 2000).  These transporters include Ntcp, Bsep, Mrp3, and Mrp2.  
Cholestasis is associated with the upregulation of Mrp3 (Soroka et al, 2001; Donner and 
Keppler, 2001), the down-regulation of Ntcp and Mrp2 (Trauner et al, 1997; Lee et al, 
2000), and relatively normal expression of Bsep (Lee et al, 2000).  Changes to transporter 
activity can be caused by two different events, one event being mutation in the gene 
encoding the transporter, and the other event being a change in the translocation of the 
transporters responsible for the movement of bile acids through the hepatocyte. 
 A mutation in the gene encoding Bsep results in type 2 progressive familial 
intrahepatic cholestasis (PFIC2) (Strautnieks et al, 1998), while mutations in Mdr3 and 
Mrp2 result in type 3 progressive familial intrahepatic cholestasis and Dubin-Johnson 
syndrome, respectively (Paulusma et al, 1997; De Vree et al, 1998).  Cholestasis can also 
be induced using different chemicals, which include taurolithcholate (TLC) and estradiol-
17β-D-glucaronide, which aid in the removal of Bsep and Mrp2 from the canalicular 
membrane (Mottino et al, 2002; Crocenzi et al, 2003).  Thus, when hepatocytes are 
treated with these chemicals, the proteins are unable to transport bile salts, and 
cholestasis occurs. 
 In addition to decreased movement of bile acids due to a change in translocation 
of transporters to the basolateral and canalicular membranes, cholestasis can also be 
caused by disturbing the flow of bile through damaged intrahepatic bile ductules (Jansen, 
2000).  This is the case in primary biliary cirrhosis (PBC), as the bile ducts are damaged 
in this disease.  Jaundice is a symptom of PBC, and is a result of cholestasis and the 
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inability of the hepatocytes to secrete bilirubin (Jansen, 2000).  This type of cholestasis is 
experimentally induced via bile duct ligation. 
TABLE 2:  SUMMARY OF TYPES OF CHOLESTASIS.  A 
summary of the known types of cholestasis, along with the cause of 
each type (Trauner et al., 1999). 
Disease Molecular Change 
Acquired  
Primary Biliary Cirrhosis AE2 mRNA and protein reduced; hepatocytes and cholangiocytes are affected;MDR3 mRNA levels 
unchanged 
Extrahepatic Biliary Atresia NTCP mRNA reduced. Inverse correlation with serum bilirubin levels 
increase after successful Kasai procedure 
Primary Sclerosing Cholangitis OATP mRNA increased 
 
Biliary Obstruction MDRl and MDR3 mRNA increased. Direct correlation with serum 104 
bilirubin levels 
Hereditary  
Progressive Familial Intrahepatic Cholestasis 
(PFIC) 
 
PFIC-1 Mutation of FICI gene (chromosome 18q21--22): 
low y-CT 
PFIC-2 Mutation of BSEP gene (chromosome 2q24); low y-
CT; canalicular BSEP protein absent 
PFIC-3 Mutation of A4DR3 gene (chromosome 7q21); high 
y-CT; canalicular MDR3 protein absent 
Benign Recurrent Intrahepatic Cholestasis (BRIC) Mutation of FICI gene (chromosome 18q21l22) 
Dubin-Johnson Syndrome Mutation of MRP2 gene (lOq23-24) 
Canalicular MRP2 protein absent 
  
 
Mrp2 
 
Mrp2 stands for multidrug resistance associated transporter 2.  It is also known as 
cMOAT, or canalicular membrane organic anion transporter. 
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Characterization of Structure 
 This protein is a part of a superfamily of transporter proteins known as the 
ATP-binding cassette proteins (ABC).  These proteins hydrolyze ATP to ADP and Pi to 
provide energy to transport solutes against a concentration gradient (Takikawa, 2002). 
Within this large family of proteins, there are seven subfamilies, which include ABC1, 
MDR/TAP, MRP, ALD, OABP, GCN20, and White groups (Borst et al, 2000).  Mrp2 is 
a part of the multidrug resistance protein (MRP) subfamily.  Proteins in this family are 
responsible for carrying a wide range of drugs out of cells, making them suspects in many 
unexplained drug-resistance cases, though no clear connection has been identified (Borst 
et al, 2000).  Mrp2 is 1541 amino acids long and contains 6 different regions (Genbank 
Protein ID: NP 036965).  The amino acid sequence of Mrp2 is shown in figure 3.  It also 
contains 16 transmembrane domains (SOSUI), shown in table 3.   
1    mdkfcnstfw dlsllespea dlplcfeqtv lvwiplgflw llapwqlysv yrsrtkrssi 
61   tkfylakqvf vvfllilaai dlslaltedt gqatvppvry tnpilylctw llvlavqhsr 
121  qwcvrknswf lslfwilsvl cgvfqfqtli rallkdsksn maysylffvs ygfqivllil 
181  tafsgpsdst qtpsvtasfl ssitfswydr tvlkgykhpl tledvwdide gfktrsvtsk 
241  feaamtkdlq karqafqrrl qksqrkpeat lhglnkkqsq sqdvlvleea kkksekttkd 
301  ypkswliksl fktfhvvilk sfilklihdl lvflnpqllk lligfvkssn syvwfgyica 
361  ilmfavtliq sfclqsyfqh cfvlgmcvrt tvmssiykka ltlsnlarkq ytigetvnlm 
421  svdsqklmda tnymqlvwss viqitlsiff lwrelgpsil agvgvmvlli pvngvlatki 
481  rniqvqnmkn kdkrlkimne ilsgikilky fawepsfqeq vqgirkkelk nllrfgqlqs 
541  llifilqitp ilvsvvtfsv yvlvdsanvl naekaftsit lfnilrfpls mlpmvtssil 
601  qasvsvdrle rylggddldt sairrvsnfd kavkfseasf twdpdleati qdvnldikpg 
661  qlvavvgtvg sgksslvsam lgemenvhgh itiqgstayv pqqswiqngt ikdnilfgse 
721  ynekkyqqvl kacallpdle ilpggdmaei gekginlsgg qkqrvslara ayqdadiyil 
781  ddplsavdah vgkhifnkvv gpngllagkt rifvthgihf lpqvdeivvl gkgtilekgs 
841  yrdlldkkgv farnwktfmk hsgpegeatv nndseaeddd dgliptmeei pedaaslamr 
901  renslrrtls rssrsssrrg kslknslkik nvnvlkekek evegqklikk efvetgkvkf 
961  siylkylqav gwwsilfiil fyglnnvafi gsnlwlsawt sdsdnlngtn nssshrdmri 
1021 gvfgalglaq gicllistlw siyacrnask alhgqlltni lrapmrffdt tptgrivnrf 
1081 sgdistvddl lpqtlrswmm cffgiagtlv micmatpvfa iiiiplsily isvqvfyvat 
1141 srqlrrldsv tkspiyshfs etvtglpiir afehqqrfla wnekqidinq kcvfswitsn 
1201 rwlairlelv gnlvvfcsal llviyrktlt gdvvgfvlsn alnitqtlnw lvrmtseaet 
1261 nivaverise yinveneapw vtdkrppadw prhgeiqfnn yqvryrpeld lvlkgitcni 
1321 ksgekvgvvg rtgagksslt nclfrilesa ggqiiidgid vasiglhdlr erltiipqdp 
1381 ilfsgslrmn ldpfnkysde evwralelah lrsfvsglql gllsevtegg dnlsigqrql 
1441 lclgravlrk skilvldeat aavdletdsl iqttirkefs qctvitiahr lhtimdsdki 
1501 mvldngkive ygspeellsn rgsfylmake agienvnhte l 
 
FIGURE 3: Mrp2 AMINO ACID SEQUENCE.  (Genbank Protein 
ID: NP 036965) 
 
 14
TABLE 3: TRANSMEMBRANE DOMAINS OF Mrp2.  The amino 
acid sequences of the Mrp2 transmembrane segments, and their 
locations within the overall protein (SOSUI).  
No. 
N 
terminal 
Transmembrane region 
C 
terminal 
Type Length 
1 27 EQTVLVWIPLGFLWLLAPWQLYS 49 Primary 23 
2 63 FYLAKQVFVVFLLILAAIDLSLA 86 Primary 23 
3 99 RYTNPILYLCTWLLVLAVQHSRQ 121 Primary 23 
4 131 LSLFWILSVLCGVFQFQTLIRAL 153 Primary 23 
5 163 YSYLFFVSYGFQIVLLILTAFS 184 Primary 22 
6 319 LKSFILKLIHDLLVFLNPQLLKL 341 Primary 23 
7 352 YVWFGYICAILMFAVTLIQSFCL 374 Primary 23 
8 431 TNYMQLVWSSVIQITLSIFFLWR 453 Secondary 23 
9 458 SILAGVGVMVLLIPVNGVLATK 479 Primary 22 
10 542 LIFILQITPILVSVVTFSVYVLV 564 Primary 23 
11 580 TLFNILRFPLSMLPMVTSSILQA 602 Secondary 23 
12 975 ILFIILFYGLNNVAFIGSNLWLS 997 Primary 23 
13 1020 IGVFGALGLAQGICLLISTLWSI 1042 Primary 23 
14 1095 LRSWMMCFFGIAGTLVMICMATP 1117 Primary 23 
15 1121 IIIIPLSILYISVQVFYVATSRQ 1143 Primary 23 
16 1213 LVVFCSALLLVIYRKTLTGDVVG 1235 Primary 23 
 
 
 The Mrp2 protein is 174.19 kD in size (Gillin et al, 2004).  The ABC 
transporter transmembrane region is found from amino acids 318-589.  The ABC-type 
multidrug transport system, ATPase and permease components are found from amino 
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acids 306-857, and the ABC transporter nucleotide-binding domain is found from 633-
841.  Another set of these three components completes the six regions; these are found 
from amino acids 975-1252, 1020-1534, and 1296-1514 respectively. The ABC 
transporter region is made up of six transmembrane helices, and Mrp2 has two ABC 
transporter regions used to bind ATP to provide energy for solute transport, much like 
other transporters in the ABC family (Genbank Protein ID: NP 036965).   
 The ABC-type multidrug transport system, ATPase, and permease components 
are made up of many transmembrane domains, and may take part in a defense system. 
The ABC transporter nucleotide-binding domain is made up of a “signature motif, Q-
loop, and H-loop/switch region in addition to the Walker A motif/P-loop and Walker B 
motif commonly found in a number of ATP- and GTP-binding and hydrolyzing proteins” 
(Genbank Protein ID: NP 036965). 
 The gene for Mrp2 (Gene ID: 25303) is located on chromosome one, and it is 
called Abcc2.  The following figures show both the gene and its transcripts and products; 
the gene is located at the 1q51-q55 location of the chromosome (Genbank Gene ID: NP 
25303).  
 
FIGURE 4:  Mrp2 GENE STRUCTURE.  Illustrates the Abcc2 gene 
encoding Mrp2 (Genbank, GeneID: 25303). 
 
 
 
 
FIGURE 5:  Mrp2 GENE PRODUCTS.  Shows the products of the 
Abcc2 gene (Genbank). 
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Role of Mrp2 in Bile Transport 
 Mrp2 is localized to the canalicular membrane of the hepatocyte, and its 
substrates include dinitrophenyl-S-glutathione, sulfotaurolithocholate, 
bilirubinmonoglucuronide and diglucuronide, 17b-estradiol glucuronide, glutathione 
conjugates, leukotriene C4, and glutathione disulfide (GSSG) (Meier and Steiger, 2000).  
It is responsible for transporting glutathione (GSH) and other glutathione, glucuronide, 
and sulfate conjugates into bile (Mottino et al, 2002).  In addition, although Mrp2 is not 
responsible for transporting taurocholic acid, a substitution of leucine from arginine at 
either position 586 or 1096 can make the protein able to transport it (Ito et al, 1998).  This 
could indicate that all of the bile acid transporters are similar in structure. 
 In order for Mrp2 to secrete any of these substances into bile, it must first be 
translocated to the canalicular membrane, since it is inactive when present in the cytosol.  
This translocation is mediated by cyclic AMP (cAMP), shown in 1998 when treatment of 
hepatocytes with DBcAMP caused Mrp2 to move to the apical membrane (Roelofsen et 
al, 1998).  A mechanism for this movement was proposed.  At one hour after treatment, 
Mrp2 is present at points in the plasma membrane or is located in vesicles just underneath 
it.  These vesicles are believed to contain Mrp2.  Mrp2 is then spread throughout the 
plasma membrane when vesicles migrate to the membrane and fuse with it.  At three 
hours after treatment, Mrp2 is spread throughout the apical membrane (Roelofsen et al, 
1998). 
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Mrp2 in Cholestasis 
 A mutation in Mrp2 is indicated in Dubin-Johnson syndrome, a type of 
cholestasis.  This has been shown in a study involving Wistar rats which are transport 
deficient (TR-).  These rats show many similar symptoms to Dubin-Johnson patients 
(Zimniak, 1993).  The first of these symptoms is chronic conjugated hyperbilirubinemia, 
along with the inability to clear injected bromosulfopthalein from the liver, and 
regurgitatation of glutathione conjugate into the cytosol (Mandema, 1960).  There is an 
increased urinary secretion of coproporphyrin I, a byproduct of heme synthesis (Jansen, 
1985).  Finally, liver biopsies of Dubin-Johnson patients show lysosomal accumulation of 
black pigment, which is also seen in rats whose diet is supplemented with aromatic amino 
acids (Zimniak, 1993). 
 In addition to mutations in the DNA encoding the protein, cholestasis can also be 
induced by a variety of agents and methods.  Bile duct ligation, endotoxin, TLC, and 
estradiol-17 β-D-glucaronide (E217G) cause the internalization of Mrp2 in the cell 
(Trauner et al, 1997), which in turn causes cholestasis. 
 E217G has been shown to cause removal of Mrp2 from the plasma membrane, 
resulting in an accumulation of Mrp2 in the cytosol (Mottino et al, 2002).  However, 
when the cells are pretreated with cAMP, the effects of E217G are reversed within three 
hours of the treatment.  This suggests that more Mrp2 is present in the plasma membrane 
as a result of the treatment with cAMP, so there is more to be removed when treated with 
E217G (Mottino et al, 2002). 
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Role of cAMP and PKCδ in Translocation of Mrp2: Anwer Lab Experiments 
 Protein kinase C (PKC) is a family of at least 12 isozymes (Newton, 2003).  
Within this family, there are different subgroups, such as the conventional PKCs (PKCα, 
β, βI, βII, and γ), novel PKCs (PKCδ, ε, η and θ), atypical PKCs (PKCζ and λ), and 
PKCµ.  These different families are designated cPKC, nPKC, and aPKC respectively.  
The cPKCs are dependent on Ca2+ and diacylglycerol, while nPKCs are Ca2+ 
independent, and aPKCs are independent of both calcium and phospholipids.  The PKC 
of importance in this study was nPKCδ, which is present in rat hepatocytes (Beuers et al, 
1999).  It is thought that PKCδ is activated by a PI3K signaling pathway, although this 
has not been proven. 
 It has already been shown that cAMP is involved in the translocation of Mrp2 to 
the plasma membrane; however, the biochemical pathway by which it does so is 
unknown.  The aim of a study completed in the Anwer lab was to determine whether 
cAMP reversed the effects of TLC-induced internalization of Mrp2, whether cAMP 
activates PKCδ, and whether PKCδ mediates the translocation of Mrp2 with cAMP 
(Gillin et al, 2004). 
 In the first part of this Anwer lab study, rat hepatocytes were isolated and treated 
first with cAMP and then TLC.  The results showed that cAMP reversed TLC-mediated 
internalization of Mrp2, which is shown in figure 6. 
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 FIGURE 6: cAMP REVERSES TLC-INDUCED INTERNAL-
IZATION OF Mrp2.  Shows the amount of Mrp2 present in the 
plasma membrane increases as a result of treatment with cAMP or 
cAMP + TLC relative to TLC alone (Gillin et al, 2004). 
 
 
 Additionally, hepatocytes were treated with increasing amounts of cAMP, and 
then the amount of PKC present in the plasma membrane was analyzed.  The results 
showed that cAMP does indeed activate PKC, summarized in figure 7. 
 
 
FIGURE 7: cAMP ACTIVATES PKCδ.   Shows the relative values 
of membrane and total PKC as a result of treatment with increasing 
concentrations of cAMP (Anwer, 2001). 
 
 
 Finally, hepatocytes were treated with Rottlerin, a known inhibitor of PKCδ.  
Both the amount of membrane/total PKCδ and the amount of Mrp2 present in the plasma 
membrane were analyzed.  The results showed that Rottlerin inhibited both translocation 
of PKCδ and translocation of Mrp2, suggesting that PKCδ plays a role in the 
translocation of Mrp2 to the plasma membrane.  A summary of these results is shown in 
figure eight. 
 20
       
FIGURE 8: AN INHIBITOR OF PKCδ INHIBITS cAMP-
INDUCED TRANSLOCATION OF Mrp2 AND PKCδ.   Shows the 
effect of cAMP +/- Rottlerin on plasma membrane and the relative 
membrane/total PKCδ (Gillin et al, 2004). 
 
  
 Based on these results, the authors hypothesized cAMP-induced Mrp2 
translocation may be mediated via activation of PKCδ.  Although some of the pathways 
are not yet known, the hypothesis is summarized in figure 9. 
 
 
FIGURE 9: SIGNALING PATHWAY OF Mrp2 
TRANSLOCATION.  Shows the proposed signaling pathway for the 
translocation of Mrp2 to the canalicular membrane (Anwer, 2001). 
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PURPOSE OF THE MQP 
 
The study that we performed was directly related to this proposed mechanism 
pathway of Anwer, 2001, as we attempted to determine whether cAMP induced 
translocation of Mrp2 to the plasma membrane through the activation of PKCδ.  
Bistratene A (BisA), isolated from the marine sponge Lissoclinium bistratum, is a known 
selective activator of PKCδ (Frey et al, 2001) and was used to treat primary hepatocytes 
in culture; then, the cells were biotinylated to label surface proteins.  If cAMP induces 
translocation of Mrp2 by activating PKCδ, then an activator of PKCδ should also 
independently induce Mrp2 translocation.  This can be detected by precipitating the 
biotinylated membrane proteins by using streptavidin beads, which show an affinity for 
biotin (Manufacturer’s Information: purchased from Novagen).  These proteins can be 
separated via SDS/PAGE and transferred to a nitrocellulose membrane.  Then, the levels 
of Mrp2 can be quantified by Western blotting specifically for Mrp2.  In addition, Mrp2 
will be probed for in the whole cell lysate (non-precipitated with streptavidin beads) to 
make sure there is approximately equal amounts of Mrp2 protein in each cell sample. 
If BisA is shown to translocate Mrp2, then the hypothesis that PKCδ translocates 
Mrp2 would be supported.  If the translocation effect of BisA and cAMP are not 
summative, then it is likely that they act via the same pathway, and since BisA is known 
to be an activator of PKCδ, it can be extrapolated that cAMP translocates Mrp2 via 
PKCδ. 
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MATERIALS AND METHODS 
 
 
Hepatocyte Harvesting 
Cell Acquisition 
 Hepatocytes were harvested from the livers of Male Wistar rats (200-300 g) 
obtained from Charles River Laboratories.  Hepatocytes were isolated from the rat livers 
through collagenase perfusion (Anwer et al, 1976).  The collagenase was purchased from 
Sigma. 
 
Cell Treatment 
 Prior to cell treatment, cells were suspended in a Hepes assay buffer at pH 7.4 for 
thirty minutes at 37˚C.  The buffer contained each of the following in mM: 20 HEPES, 
140 NaCl, 5 KCl, 1 MgSO4, 1.0 CaCl2, 0.8 KH2PO4, and 5 glucose.   
 There were eight different treatment groups for the cells.  The first group was 
treated with DMSO, the second with DMSO and 100 µM cAMP (purchased from 
Sigma), the third with 50 µM Bistratene A (BisA) (purchased from Sigma) and DMSO, 
the fourth with 50 µM BisA and 100 µM cAMP, the fifth with 100 µM BisA and DMSO, 
the sixth with 100 µM BisA and 100 µM cAMP, the seventh with 200 µM BisA and 
DMSO, and the eighth with 200 µM BisA and 100 µM cAMP.  Cells were treated for 30 
minutes with 1 mL of treatment solution, at which point the treatments were stopped by 
washing the cells in ice cold PBS.   
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Cell Biotinylation and Lysis
Cell Biotinylation 
 0.5 mg/mL biotin was made by dissolving biotin in PBS pH 8.0.  This biotin was 
ice cold.  Cells were biotinylated by adding 1.5 mL of this solution to the cells and 
rocking the cells at 4˚C for forty-five minutes.  Afterwards, the cells were washed three 
times with ice cold PBS to remove the excess biotin. 
 
Preparation of Cell Lysates 
 After biotinylation, the cells were lysed with one mL of cell lysis buffer (CLB+) 
per sample.  The cell lysis buffer contained each of the following (all constituents of 
CLB+ purchased from Sigma): 20 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 500 
nM okadaic acid, and 1 mM orthovanadate.  After the lysis buffer was added to the cells, 
the cells were vortexed every ten to fifteen minutes for forty-five minutes, sitting on ice 
in between vortexing. Afterwards, these tubes were centrifuged at 14,000 rpm for 10 
minutes, and the supernatants were removed into new tubes.  These supernatants were the 
lysates used for the experiment. 
 
Protein Concentration Determination by Lowry Assay 
 The concentration of total protein for each cell treatment sample was determined 
by performing a Lowry Assay (Lowry et al, 1951).  In this assay, a standard curve for 
protein of known concentration (protein standard 60 g/L) was constructed, and the 
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unknown concentrations of sample proteins were determined by plotting them against the 
standard curve. 
 
Purification of Biotinylated Proteins 
 Streptavidin beads (purchased from Novagen) were pre-cleared by washing them 
four times in an excess of PBS pH 8.0, centrifuging between each wash.  After the 
washes, the beads were transferred to a new tube and adjusted to a 50:50 slurry of 
streptavidin beads: PBS pH 8.0. 
 300 µg of lysate protein for each sample was added to a different tube, and 50 µL 
of pre-cleared streptavidin bead slurry was added to each sample.  Then, 100 µL of PBS 
pH 8.0 was added to each sample.  Samples were rotated at room temperature for thirty 
minutes and then centrifuged at 14,000 rpm for one minute at room temperature.  
Samples were then washed three times with one mL of PBS pH 8.0, after which all PBS 
was removed, leaving only the bead-protein conjugate behind.   
 
Immunoblot (Western) Analysis 
SDS/PAGE 
 10 µL of β-mercaptoethanol (purchased from BIORAD) was added to 500 µL of 
SDS gel loading buffer, and 30 µL of this solution was added to each precipitated protein 
sample.  Samples were allowed to incubate for five minutes so that the proteins would 
separate from the streptavidin beads. 
Whole cell lysates, whose biotinylated proteins had not been precipitated with 
streptavidin beads, were also prepared for gel loading.  100 µg of total protein was loaded 
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for each of these samples, and β-mercaptoethanol with 3X SDS was added to the protein 
in such a way that it was one third of the total protein volume. 
 Two ten lane, six percent SDS polyacrylamide were made.  Precipitated proteins 
were loaded to one gel, keeping the beads left behind in the sample tube.  Non-
precipitated lysates were loaded to another gel.  After loading, 10 more µL of β-
mercaptoethanol with 3X SDS was added to each lane in the gel.  High molecular weight 
and kaliedoscope protein standards were used for size markers (both purchased from 
BIORAD).  Then, the proteins were subjected to SDS/PAGE at 180 Volts for 55 minutes.
 After SDS/PAGE was complete, gels were placed into a transfer apparatus.  The 
proteins were transferred to a nitrocellulose membrane (purchased from BIORAD) at 100 
Volts for 75 minutes.  After the transfer, the gels were placed in a Coomassie Blue stain, 
and the immunoblots were labeled and subjected to antibody treatments. 
 
Detection of Proteins by Antibodies 
 The nitrocellulose membranes were blocked for one hour at room temperature 
with bovine serum albumin (BSA) 5% (purchased from SIGMA) and TBST (distilled 
water, 10% TBS 10X, and 0.1% Tween (purchased from ACROS)).  TBS consists of 200 
mM Tris base and 1370 mM NaCl.  Afterwards the blots were washed three times with 
TBST. 
 The blots were incubated with rabbit anti-Mrp2 (donated by Dr. D. Keppler at the 
German Cancer Research Center in Heidelberg, Germany) diluted at 1:3000 with 5% 
BSA/TBST overnight at 4˚C.  Afterwards the blots were washed three times with TBST. 
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 The blots were incubated with goat-anti rabbit HRP (purchased from BIORAD) 
diluted at 1:1000 with 5% non-fat milk (purchased from BIORAD) / TBS for two hours 
at room temperature.  Afterwards, the blots were washed three times with TBSR. 
 
Detection of Proteins via ECL 
 10 mL of ECL A was combined with 10 mL of ECL B (fluids purchased from 
Santa Cruz), and the blots were bathed in this solution for one minute.  Then, the blots 
were placed into a transparent plastic folder, and the air bubbles were pressed out as the 
folder was sealed.  This folder was taped into an X-Ray cassette.  
 X-ray films were exposed to the blots for varying amounts of time (1 second to 2 
minutes) and subsequently developed.  Ideal exposures were marked and scanned into 
Adobe Acrobat (Adobe System Inc, San Jose, CA).  Protein signal intensities were 
quantified by the program SigmaGel (Jandel Scientific Software, San Rafael, CA). 
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RESULTS 
 
 Rat primary hepatocyte cultures were stimulated with various treatments, then the 
cell surface proteins were biotinylated and purified by streptavidin precipitation.  When 
subject to SDS/PAGE and Western blotting (primary blot rabbit anti-Mrp2, secondary 
goat-anti-rabbit HRP, detect via ECL), protein MRP2 shows up strongly at 174.19 kD 
(Figure 10, arrow on right side).   
 
       1         2         3        4           5          6          7         8         9       10 
FIGURE 10:  PRECIPITATION OF BIOTINYLATED Mrp2 
FROM THE HEPATOCYTE CELL SURFACE (Example western 
1 of 3).  Radiograph developed after exposing a precipitated Mrp2 
Western blot to ECL and exposing the blot to film for five seconds.  
Primary rat hepatocyte cells were biotinylated, and the proteins were 
precipitated by streptavidin beads.  The precipitated proteins were 
subjected to SDS/PAGE on a 6% gel.  The arrow on the right denotes 
the MRP2 band at 174.19 kD.  Molecular sizes are indicated in kD at 
the left.  Lanes 1 and 10: High Molecular Weight Marker, Lane 2: 
DMSO/DMSO, Lane 3: DMSO/100 uM cAMP, Lane 4: 50 uM 
BisA/DMSO, Lane 5: 50 uM BisA/100 uM cAMP, Lane 6: 100 uM 
BisA/DMSO, Lane 7: 100 uM BisA/100 uM cAMP, Lane 8: 200 uM 
BisA/DMSO, Lane 9: 200 uM BisA/100 uM cAMP.  
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 Program SigmaGel was used to quantitate the Mrp2 signals from 3 independent 
immunoblots (table 4 and figure 11). 
TABLE 4:  RELATIVE INTENSITIES OF PRECIPITATED 
Mrp2 BANDS.  Quantitative description of the effect of BisA and 
cAMP on translocation of Mrp2 to the canalicular membrane by listing 
the relative intensities of the bands from the blots of precipitated Mrp2.  
The data from each experiment, the dates of each experiment, and the 
average values are all shown. 
Precipitated Samples 11/9/2004 11/10/2004 11/16/2004  Average 
Sample      
DMSO/DMSO 1.00 1.00 1.00  1.00 
DMSO/100 µM cAMP 0.70 1.39 6.65  2.92 
50 µM Bis A/DMSO 1.20 1.64 4.24  2.36 
50 µM Bis A/100 µM cAMP 0.98 1.29 4.28  2.18 
100 µM Bis A/DMSO 1.09 1.37 6.37  2.94 
100 µM Bis A/100 µM 
cAMP 1.04 1.29 5.34  2.56 
200 µM Bis A/DMSO 0.75 0.95 4.02  1.91 
200 µM Bis A/100 µM 
cAMP 0.42 0.81 1.27  0.83 
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FIGURE 11:  HISTOPLOT OF THE Mrp2 SIGNALS QUANTITATED IN TABLE 4. 
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The quantitated data show that cAMP stimulates translocation of Mrp2, that BisA 
stimulates translocation of Mrp2 in a dose dependent fashion, and that the effects of BisA 
and cAMP are not summative, suggesting they act via the same pathway.  Additionally, 
at around 200 µM of BisA, BisA becomes less successful at translocating protein.  This 
could be due to interference with cAMP, or perhaps BisA is toxic when in high 
concentrations.  This will be elaborated upon in the discussion. 
An important part of the experimental procedure was to establish that the total 
amount of Mrp2 in each hepatocyte lysate sample was approximately the same.  If this 
was not the case, then it would be possible that an increase in Mrp2 intensity in the 
membrane was not due to increased translocation.  Figure 12 is a close-up of a Western 
blot of Mrp2 from the whole cell lysate (non-streptavidin-precipitated protein).  Visually, 
it appears that the Mrp2 intensities are similar.  Table five and figure 13 support this idea, 
showing that there is only a 13% variation of total Mrp2 among all of the samples.  There 
was no statistical difference between the intensities of the protein (T-test, p = 0.98).  
 1 2      3  4      5  6        7  8 
 
FIGURE 12:  DIRECT QUANTITATION OF PROTEIN Mrp2 
LEVELS IN THE HEPATOCYTE LYSATES.    Image of a 
radiograph developed after exposing an Mrp2 whole cell lysate 
Western blot to ECL and exposing the blot to film for ten seconds.  The 
whole cell lysates were subject to SDS/PAGE on a 6% gel for 55 
minutes at 180 V.   See the method section for more detail regarding 
the experimental techniques. Lane 1: DMSO, Lane 2: DMSO/100 uM 
cAMP, Lane 3: 50 uM BisA/DMSO, Lane 4: 50 uM BisA/100 uM 
cAMP, Lane 5: 100 uM BisA/DMSO, Lane 6: 100 uM BisA/100 uM 
cAMP, Lane 7: 200 uM BisA/DMSO, Lane 8: 200 uM BisA/100 uM 
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cAMP.  Bands appear to have similar intensities of darkness, 
suggesting the Mrp2 protein was loaded in similar amounts. 
 
 
TABLE 5:  QUANTITATION OF Mrp2 PROTEIN LEVELS 
FROM FIGURE 13. Table five shows a quantitative description of the 
intensities of MRP2 bands from whole cell lysate samples.  The dates 
of each experiment are shown. Although somewhat variable, the 
standard deviation of the values is only 0.14 (the average is 0.77). 
Statistically, there is no difference (t test, p = 0.98) 
 
Whole Cell Lysates 11/9/2004 11/10/2004 11/16/2004  Average 
Sample      
DMSO/DMSO 1.00 1.00 1.00  1.00 
DMSO/100 µM cAMP 0.65 1.25 0.66  0.86 
50 µM Bis A/DMSO 0.94 1.24 0.50  0.90 
50 µM Bis A/100 µM cAMP 0.80 1.01 0.39  0.73 
100 µM Bis A/DMSO 0.68 1.05 0.35  0.69 
100 µM Bis A/100 µM 
cAMP 0.89 0.88 0.30  0.69 
200 µM Bis A/DMSO 0.50 1.05 0.25  0.60 
200 µM Bis A/100 µM 
cAMP 0.70 0.96 0.38  0.68 
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  FIGURE 13:  HISTOPLOT OF THE DATA FROM TABLE 5.   
  Represents the data from table 5 graphically showing approximately  
  equal loading of protein Mrp2 input for streptavidin precipitation. 
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 As stated in the project purpose, a fundamental part of this project was to show 
that BisA stimulates the translocation of Mrp2 to the hepatocyte cell surface.  Figure 14 
represents a plot of the average Mrp2 protein levels versus BisA concentration taken 
from the previous data.  The data very clearly illustrates that BisA can indeed stimulate 
translocation of Mrp2 from the cytosol to the membrane in a dose dependent fashion.  For 
some reason, between 100 uM and 200 uM of BisA, BisA starts losing its ability to 
translocate Mrp2.  The reasons for this are unknown, but it is possible that at such high 
concentrations, BisA can be toxic or losing its specificity.  
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FIGURE 14:  BIS-A TRANSLOCATES Mrp2 TO THE 
HEPATOCYTE MEMBRANE.    Plot of the average of 3 
independent experiments discussed previously.  BisA activates 
translocation up through 100 µM, but at 200 µM, it begins to lose this 
ability. 
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 If BisA and cAMP act by separate pathways, one would expect treating a cell 
with both chemicals to double the translocation of Mrp2.  However, if they acted via the 
same pathway, the translocation when treating the cells with both chemicals would be the 
same as if treating with one of the chemicals.  The data (figure 15, replotted from figure 
13) supports the latter, as there is no statistical difference between the translocation from 
BisA alone or BisA with cAMP (2 sample T test, p = 0.42).  Thus, the data support that 
these two activators translocate Mrp2 by the same pathway.  Since it is already known 
that BisA activates PKCδ, and it has been shown that cAMP translocates PKCδ (Gillin et 
al, 2004), it can be deduced that cAMP translocates Mrp2 by activating PKCδ.  
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FIGURE 15:  THE TRANSLOCATION OF Mrp2 BY cAMP AND 
BIS-A IS NOT ADDITIVE.   This figure compares the translocation 
of Mrp2 to the hepatocyte membrane by BisA alone and BisA plus 
cAMP.  As already shown, BisA activates translocation of Mrp2 to the 
membrane up until 200 uM BisA.  BisA, when combined with 100 uM 
cAMP, also stimulates translocation of Mrp2 to the membrane up until 
200 uM BisA.  It is important to note that the effects of BisA and 
cAMP are not summative; they are the same as BisA alone (T test, p = 
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0.42), suggesting that BisA and cAMP are acting through the same 
pathway. 
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DISCUSSION 
 
The purpose of this report was to investigate whether cAMP stimulates the 
translocation of Mrp2 by activating PKCδ.  The Anwer lab’s model of Mrp2 
translocation from the hepatocyte cytosol to the canalicular membrane suggested that this 
is the case.  It had already been shown that Mrp2 is downregulated in cholestasis 
(Trauner et al, 1997; Beuers et al, 2003). It had also been shown that cAMP can not only 
stimulate translocation of Mrp2 to the canalicular membrane under normal conditions 
(Roelofsen et al, 1998), but also that cAMP can also restore Mrp2 translocation under 
estradiol-induced cholestasis (Mottino et al, 2002).   
Anwer’s lab at Tufts University School of Veterinary Medicine was able to build 
upon this information already presented by associating the cAMP-induced translocation 
of Mrp2 with the translocation of a protein kinase named PKCδ.  Their experiment 
showed that cAMP stimulated translocation of PKCδ to the canalicular membrane in a 
dose dependent fashion (Gillin et al, 2004).  Thus, they hypothesized that cAMP may 
translocate Mrp2 to the canalicular membrane by activating PKCδ.  Further experiments 
performed by the Anwer lab supported this idea, because Rottlerin, an inhibitor of PKCδ, 
prevented cAMP from translocating Mrp2 (Gillin et al, 2004).  In effect, they had 
provided evidence cAMP acts via PKCδ, because when the inhibitor of PKCδ was used 
to treat the cells, cAMP’s action was hindered. 
This Anwer lab experiment provided reason to test the hypothesis that cAMP 
translocates Mrp2 via activation of PKCδ by treating the cells with a known activator of 
PKCδ, Bistratene A. This was the goal of the MQP.  Rat hepatocyte cell membrane 
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proteins were detected by biotinylating the cells (biotin binds only to surface proteins 
under the experimental conditions used).  Mrp2 was detected from that solution via 
specific antibodies through Western blotting.   
Figure 16 represents the working hypothesis (and the alternate hypothesis, which 
would be that PKCδ and cAMP act via separate pathways to translocate Mrp2).  If PKCδ 
and cAMP acted via separate pathways, then if both were used to treat the cells, they 
would have summative effects on the translocation of Mrp2.  This is represented by the 
pink line in the figure, which is a curve with the expected relative intensity (sum of 
cAMP and respective BisA translocations).  If PKCδ and cAMP acted via the same 
pathway, the translocation should not differ if only BisA were used to treat the cells or if 
BisA and cAMP were used together to treat the cells.   
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FIGURE 16:  SUPPORTIVE AND ALTERNATIVE 
HYPOTHESES FOR THE EFFECTS OF cAMP AND BIS-A ON 
Mrp2 TRANSLOCATION.  The main hypothesis of this MQP is that 
cAMP induces the translocation of Mrp2 to the hepatocyte membrane 
using PKC-delta, thus the effects of cAMP (which translocates Mrp2) 
plus BisA (a known PKC-delta activator) should not be additive (blue 
line).  The alternative hypothesis (pink line) would be that BisA and 
cAMP activate translocation of Mrp2 to the membrane via different 
pathways, so if both BisA and cAMP were used to treat the cells, then 
the effects would be summative, and there would be twice as much 
translocation as if BisA were used alone.  Our data support the former 
hypothesis. 
 
 Table four, figure 11, and figure 14 were successful in showing that BisA does 
stimulate translocation of Mrp2 into the hepatocellular membrane until a concentration of 
200 µM.  Table five and figure 13 show that the amounts of whole cell lysate did not 
vary.  This indicates that the amounts of Mrp2 loaded onto the gel are equal.  
Furthermore, the amounts of total Mrp2 in the protein are equal. Therefore, the 
differences in the amount of Mrp2 present in the membrane are indeed due to 
translocation.   
The reason why BisA starts to lose its effect is unclear; there is the possibility that 
at a higher concentration, BisA can become toxic to the cell or lose its specificity and 
start interacting with other processes in the cell.  It is likely that there is some kind of 
interaction between BisA and cAMP at high concentrations of BisA, because at 200 µM 
of BisA only, the membrane presence of Mrp2 is 1.91, but at 200 µM of BisA and 100 
µM of cAMP, the membrane presence is only 0.83.   
Nevertheless, results obtained with 50 and 100 µM BisA are consistent with the 
idea that PKCδ alone is responsible for the translocation of Mrp2.  More importantly, in 
figure 15, there is no significant difference between the translocation of Mrp2 by BisA 
alone or by BisA and cAMP combined, suggesting that BisA and cAMP are translocating 
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Mrp2 via the same pathway.  Since BisA is the known activator of PKCδ, and PKCδ 
translocates Mrp2, it can be assumed that cAMP translocates Mrp2 via PKCδ, especially 
since it has already been shown that cAMP translocates PKCδ to the membrane (Gillin et 
al, 2004).  The specifics of the interaction between the translocation of PKCδ and the 
translocation of Mrp2 have yet to be determined, and this would be interesting to 
examine in a future experiment.  Figure 17 provides a schematic of the pathway proposed 
by this paper.  
BisA 
 
FIGURE 17: cAMP TRANSLOCATES Mrp2 VIA PKCδ 
ACTIVATION.  Schematic of the pathway that the results of this 
MQP support.  The data support the idea that BisA and cAMP activate 
Mrp2 translocation via the same pathway.  Since BisA is an activator of 
PKCδ, and since previous studies have shown that cAMP translocates 
PKCδ to the membrane, this same pathway can be assumed to be 
PKCδ.  The interaction between PCKδ and Mrp2 translocation is still 
unknown. 
 
There is one weakness of this paper.  The data for this is limited, as only three 
experiments were performed on one cell lysate.  However, even though there are only 
three experiments performed, the data was replicated three times, providing strength to 
the conclusions.  The reason for this low amount of experiments is because the MQP 
team originally was working on a different experiment that aimed to determine the 
dephosphorylation site of Ntcp.  After a month of training and learning experimental 
techniques, the team spent roughly two months on the Ntcp project.   However, the team 
MRP2 
Translocation 
 
cAMP 
PKC delta 
? 
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was unable to obtain protein concentrations high enough to produce valid results, because 
the protein signals on the Western blots were too weak.  The lab thought the reason for 
this was poor transfection success of the protein.   Since Mrp2 was obtained straight from 
rat liver and not via transfection, protein levels were much higher, and the group was able 
to obtain data from the Mrp2 experiments.  The team realizes that the data is limited, but 
because of the lack of success in obtaining Ntcp data, an experiment had to be quickly 
performed before the graduation deadline.  However, even though the earlier Ntcp 
experiments were not successful, the team did learn invaluable lab techniques. 
This experiment should be continued in order to provide more data to support the 
hypothesis with more strength.  Currently, the Anwer lab is studying PKCδ’s association 
with Mrp2 during the translocation, and results of these experiments are still pending.  
Since PKCδ is a protein kinase, it is likely that it phosphorylates a protein that continues 
downstream to translocate Mrp2, or it phosphorylates Mrp2 itself.  This mechanism by 
which PKCδ causes translocation of Mrp2 should be the focus of future studies. Also, a 
cell viability study should be performed in order to validate the idea that BisA is toxic at 
high concentrations, as well as studies showing that the activation of PKCδ still occurs 
with BisA concentrations of 200 µM, and whether 200 µM BisA and 100 µM cAMP 
together may actually inhibit PKCδ.   
In conclusion, this MQP has provided preliminary data that Mrp2 is translocated 
from the hepatocellular cytosol to the canalicular membrane when cAMP activates 
PKCδ.  These data provide a foundation for the support of this hypothesis, helping to 
provide more knowledge about the disease state of cholestasis.  Hopefully, with these 
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data, the molecular pathophysiology of cholestasis will be better characterized, and more 
successful treatments for the disease will be developed. 
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